Spectrum Pharma (SPPI) Tops Q3 EPS by 8c
Get Alerts SPPI Hot Sheet
Price: $1.03 --0%
EPS Growth %: +100.0%
Financial Fact:
Other income, net: 372K
Today's EPS Names:
CP, RUSHA, SEIC, More
EPS Growth %: +100.0%
Financial Fact:
Other income, net: 372K
Today's EPS Names:
CP, RUSHA, SEIC, More
Join SI Premium – FREE
Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35).
“The third quarter was marked by significant progress in our drug development programs and a strengthened financial position,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “Our team is preparing for the upcoming pre-NDA meeting with the FDA for poziotinib and actively working to obtain an approval for ROLONTIS as soon as possible.”
For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Innodata (INOD) Awarded New Programs from "Magnificent Seven" Big Tech Customer Valued at Approximately $20 Million in Annualized Run Rate Revenue
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!